/
Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in th…
$25.83
$0.12 (-0.46%)
EOD Jul 17, 2026
16.86% operating margin is respectable but not wide. ROIC at 7.39%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 6.2%, steady but not accelerating. Free cash flow declined 28% despite revenue growth, conversion is weakening.
Free cash flow declined 28% versus the prior year, cash generation momentum has weakened. Net debt of $3.67B represents 12.9x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4.89B
▲ +6.2% YoY
Net Income (TTM)
-$242M
▼ -168.6% YoY
Op. Margin
17.43%
▲ +5.9pp YoY
ROIC
7.48%
▲ +4.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$315M
▼ -27.9% YoY
Op. Cash Flow (TTM)
$577M
▲ +3.5% YoY
Net Debt
$3.64B
Cash & Equiv.
$428M
5Y CAGR: +7.6%
Continue Research
Elanco Animal Health (ELAN) trades above a two-stage DCF intrinsic value of about $3.60 per share, so at $25.83 the stock looks overvalued (86.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Elanco Animal Health scores 39/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $3.60 per share for ELAN, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $2.70. At today's $25.83, that puts the stock about 86.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Elanco Animal Health scores 39 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 17.4% operating margin and a 7.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. ELAN currently trades above its estimated intrinsic value and scores 39/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.